Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report.

Fatma F Shakarchi, Joseph A Chacko, Joseph G Chacko, Rangaswamy Govindarajan, Clive S Zent, Sami H Uwaydat

Abstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatma F ShakarchiHarvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Joseph A ChackoHarvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Joseph G ChackoHarvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Rangaswamy GovindarajanWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Clive S ZentWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.

Sami H UwaydatHarvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: We demonstrate the potential role of acalabrutinib, a second-generation selective Bruton tyrosine kinase (BTK) inhibitor, as monotherapy in treating optic nerve infiltration by chronic lymphocytic leukemia (CLL). Observations: A 68-year-old male, initially diagnosed with CLL 13 years earlier, presented with a decrease in vision and intermittent floaters for 5 days. On fundus examination, there was optic disc swelling in both eyes (OU) concerning for CLL infiltration and vitreous haze in the left eye (OS). The MRI of the brain and orbit was normal, and his infectious and uveitis workups were unremarkable. He was prescribed acalabrutinib 100 mg twice daily by mouth. Five days later, the optic disc edema OU and vitreous haze OS improved and completely subsided two months later. Conclusions and importance: Early initiation of acalabrutinib may be sufficient therapy for CLL optic nerve infiltration.

Indexed as

AcalabrutinibBTK inhibitorChronic lymphocytic leukemiaCLLOptic disc edema

Identifiers

PMID42740827

DOI10.1016/j.ajoc.2026.102656

PMCPMC13571945

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.